All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Bookmark this article
The 1st Annual Meeting of the International Academy for Clinical Hematology (IACH) took place in Paris, France, on September 27–29, 2018. On Thursday 27 September, a hematology hot news session was held, with an abstract presented entitled “The RELEVANCE study” by Professor Gandhi Damaj from the University of Caen Normandy, Caen, France.
The RELEVANCE study (NCT01476787) is a multicenter, open label, randomized, phase III trial evaluating the combination of lenalidomide plus rituximab (R2) versus chemotherapy plus rituximab (R-chemo) followed by rituximab maintenance for the treatment of patients with previously untreated follicular lymphoma (FL).
Professor Damaj concluded his talk highlighting that R2 did not meet the primary objectives at the first interim analysis and R2 treatment did not show superior efficacy in comparison with R-chemo at 120 weeks. Therefore, R-chemo remains the standard of care for patients with untreated follicular lymphoma. R² could be proposed for some selected profile of patients, however, longer follow up and medico-economic data are necessary to help physician decision-making.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox